| [1] |
WISSING KM, ABRAMOWICZ D, WEEKERS L, et al. Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation[J]. Am J Transplant, 2018, 18(7):1726-1734. DOI: 10.1111/ajt.14665.
|
| [2] |
GUPTA S, POLLACK T, FULKERSON C, et al. Hyperglycemia in the posttransplant period: NODAT vs posttransplant diabetes mellitus[J]. J Endocr Soc, 2018, 2(11):1314-1319. DOI: 10.1210/js.2018-00227.
|
| [3] |
ZELADA H, VANWAGNER LB, POLLACK T, et al. Development of a predictive model for hyperglycemia in nondiabetic recipients after liver transplantation[J]. Transplant Direct, 2018, 4(10):e393. DOI: 10.1097/TXD.0000000000000830.
|
| [4] |
KE QH, HUANG HT, LING Q, et al. New-onset hyperglycemia immediately after liver transplantation: a national survey from China Liver Transplant Registry[J]. Hepatobiliary Pancreat Dis Int, 2018, 17(4):310-315. DOI: 10.1016/j.hbpd.2018.08.005.
|
| [5] |
LIU FC, LIN JR, CHEN HP, et al. Prevalence, predictive factors, and survival outcome of new-onset diabetes after liver transplantation: a population-based cohort study[J]. Medicine (Baltimore), 2016, 95(25):e3829. DOI: 10.1097/MD.0000000000003829.
|
| [6] |
ANDRADE AR, BITTENCOURT PL, CODES L, et al. New onset diabetes and non-alcoholic fatty liver disease after liver transplantation[J]. Ann Hepatol, 2017, 16(6):932-940. DOI: 10.5604/01.3001.0010.5285.
|
| [7] |
TINIAKOS DG, VOS MB, BRUNT EM. Nonalcoholic fatty liver disease: pathology and pathogenesis[J]. Annu Rev Pathol, 2010, 5:145-171. DOI: 10.1146/annurev-pathol-121808-102132.
|
| [8] |
GOLABI P, BUSH H, STEPANOVA M, et al. Liver transplantation (LT) for cryptogenic cirrhosis (CC) and nonalcoholic steatohepatitis (NASH) cirrhosis: data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016[J]. Medicine (Baltimore), 2018, 97(31):e11518. DOI: 10.1097/MD.0000000000011518.
|
| [9] |
MIKOLASEVIC I, FILIPEC-KANIZAJ T, MIJIC M, et al. Nonalcoholic fatty liver disease and liver transplantation - where do we stand?[J]. World J Gastroenterol, 2018, 24(14):1491-1506. DOI: 10.3748/wjg.v24.i14.1491.
|
| [10] |
RAHIB L, SRIRAM G, HARADA MK, et al. Transcriptomic and network component analysis of glycerol kinase in skeletal muscle using a mouse model of glycerol kinase deficiency[J]. Mol Genet Metab, 2009, 96(3):106-112. DOI: 10.1016/j.ymgme.2008.11.163.
|
| [11] |
CADOUDAL T, BLOUIN JM, COLLINET M, et al. Acute and selective regulation of glyceroneogenesis and cytosolic phosphoenolpyruvate carboxykinase in adipose tissue by thiazolidinediones in type 2 diabetes[J]. Diabetologia, 2007, 50(3):666-675. doi: 10.1007/s00125-006-0560-5
|
| [12] |
CADOUDAL T, FOUQUE F, BENELLI C, et al. Glyceroneogenesis and PEPCK-C: pharmacological targets in type 2 diabetes[J]. Med Sci (Paris), 2008, 24(4):407-413. DOI: 10.1051/medsci/2008244407.
|
| [13] |
CADOUDAL T, LEROYER S, REIS AF, et al. Proposed involvement of adipocyte glyceroneogenesis and phosphoenolpyruvate carboxykinase in the metabolic syndrome[J]. Biochimie, 2005, 87(1):27-32. doi: 10.1016/j.biochi.2004.12.005
|
| [14] |
HANSON RW, RESHEF L. Glyceroneogenesis revisited[J]. Biochimie, 2003, 85(12):1199-1205. doi: 10.1016/j.biochi.2003.10.022
|
| [15] |
BEALE EG, HAMMER RE, ANTOINE B, et al. Disregulated glyceroneogenesis: PCK1 as a candidate diabetes and obesity gene[J]. Trends Endocrinol Metab, 2004, 15(3):129-135. doi: 10.1016/j.tem.2004.02.006
|
| [16] |
BAJAJ M, SURAAMORNKUL S, ROMANELLI A, et al. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty acyl-CoAs and insulin action in type 2 diabetic patients[J]. Diabetes, 2005, 54(11):3148-3153. doi: 10.2337/diabetes.54.11.3148
|
| [17] |
HAMMOND LE, NESCHEN S, ROMANELLI AJ, et al. Mitochondrial glycerol-3-phosphate acyltransferase-1 is essential in liver for the metabolism of excess acyl-CoAs[J]. J Biol Chem, 2005, 280(27):25629-25636. doi: 10.1074/jbc.M503181200
|
| [18] |
WENDEL AA, LEWIN TM, COLEMAN RA. Glycerol-3-phosphate acyltransferases: rate limiting enzymes of triacylglycerol biosynthesis[J]. Biochim Biophys Acta, 2009, 1791(6):501-506. DOI: 10.1016/j.bbalip.2008.10.010.
|
| [19] |
STEFANO GB, FINE R, KREAM RM. Microbiome and health: ramifications of intelligent deception[J]. Med Sci Monit, 2018, 24:2060-2062. doi: 10.12659/MSM.910248
|
| [20] |
STEFANO GB, PILONIS N, PTACEK R, et al. Gut, microbiome, and brain regulatory axis: relevance to neurodegenerative and psychiatric disorders[J]. Bioc Cell Mol Neurobiol, 2018, 38(6):1197-1206. DOI: 10.1007/s10571-018-0589-2.
|
| [21] |
MILLER C, WANG L, OSTERGAARD E, et al. The interplay between SUCLA2, SUCLG2, and mitochondrial DNA depletion[J]. Biochim Biophys Acta, 2011, 1812(5):625-629. DOI: 10.1016/j.bbadis.2011.01.013.
|
| [22] |
CAPUTI V, MARSILIO I, FILPA V, et al. Antibiotic-induced dysbiosis of the microbiota impairs gut neuromuscular function in juvenile mice[J]. Br J Pharmacol, 2017, 174(20):3623-3639. DOI: 10.1111/bph.13965.
|
| [23] |
MING Y, STEFANO GB, KREAM RM, et al. Anti-diabetogenic properties of mineralocorticoid receptor antagonists: implications for enhanced safety and efficacy of post-transplantation pharmacotherapies [J]. Med Sci Monit, 2019, 25:1102-1104. doi: 10.12659/MSM.914340
|
| [24] |
罗招凡, 李芳萍, 程桦.抵抗素介导AMPK信号通路对HepG2细胞脂质代谢的影响[J].实用医学杂志, 2017, 33(11):1743-1747. DOI: 10.3969/j.issn.1006-5725.2017.11.007.LUO ZF, LI FP, CHENG Y. The effect of the recombinant human resistin on lipid metabolism by AMPK pathway in HepG2 cells[J]. J Prac Med, 2017, 33(11):1743-1747. DOI: 10.3969/j.issn.1006-5725.2017.11.007.
|
| [25] |
JAHANSOUZ C, STALEY C, KIZY S, et al. Antibiotic-induced disruption of intestinal microbiota contributes to failure of vertical sleeve gastrectomy[J]. Ann Surg, 2018. DOI: 10.1097/SLA.0000000000002729 [Epubahead of print].
|
点击查看大图
下载:
